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Abstract 
 Policy-makers play a key role in tackling the emerging public health 
problem of antibiotic resistance. Antibiotic resistance is a result of the 
misuse, and especially the overuse, of antibiotics. Antibiotic resistance leads 
to excess morbidity and deaths. The problem is urgent. In the European 
Union more than 25 000 people die each year from common resistant 
bacterial infections. Owing to variable diagnostic capacity and a lack of data 
in countries, including Albania the number for the whole Region is not 
known. Antibiotic resistance increases health care costs. The estimated total 
cost to society of antibiotic resistance in the European Union alone is 
estimated to be € 1.5 billion resistant bacteria or genes that carry this 
information can spread easily. The use of antibiotics in animals sometimes 
outweighs their use in humans. Antibiotic resistance could take us back to 
the pre-antibiotic era. The complexity of the problem and the large number 
of sectors involved require strong national coordination, surveillance 
systems, national guidelines and sector-wide action plans. Based on good 
practices of national coordination of several European countries in many 
countries serve as reference in the conclusions to develop strategic action 
plan by the Albanian health institutions that aim to: 
I. Strengthen national multi sectorial coordination for the containment of 
antibiotic resistance 
II. Strengthen national surveillance of antibiotic resistance 
III. Promote national strategies for the rational use of antibiotics and 
strengthen national surveillance of antibiotic consumption 
IV. Strengthen infection control and surveillance of antibiotic resistance in 
health care settings 
V. Prevent and control the development and spread of antibiotic resistance in 
the food chain 
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VII. Improve awareness, patient safety and partnership 
The complex nature of antibiotic resistance and the use of antibiotics requires 
the involvement of a wide array of actors: 
 
Keywords: Health policies, antibiotic resistance, interagency coordination, 
surveillance 
 
Introduction 
 Antimicrobial resistance (AMR) is resistance of a microorganism to 
an antimicrobial medicine to which it was originally sensitive. Resistant 
organisms (they include bacteria, fungi, viruses and some parasites) are able 
to withstand attack by antimicrobial medicines, such as antibiotics, 
antifungals, antivirals, and antimalarials, so that standard treatments become 
ineffective and infections persist increasing risk of spread to others. The 
evolution of resistant strains is a natural phenomenon that happens when 
microorganisms are exposed to antimicrobial drugs, and resistant traits can 
be exchanged between certain types of bacteria. The misuse of antimicrobial 
medicines accelerates this natural phenomenon. Poor infection control 
practices encourages the spread of AMR.  
 Infections caused by resistant microorganisms often fail to respond to 
the standard treatment, resulting in prolonged illness and greater risk of 
death. The death rate for patients with serious infections treated in hospitals 
is about twice that in patients with infections caused by non-resistant 
bacteria. AMR reduces the effectiveness of treatment, thus patients remain 
infectious for a longer time, increasing the risk of spreading resistant 
microorganisms to others. Many infectious diseases risk becoming 
untreatable and uncontrollable, which could derail the progress made 
towards reaching the targets of the health-related United Nations Millennium 
Development Goals set for 2015.  
 When infections become resistant to first-line medicines, more 
expensive therapies must be used. The longer duration of illness and 
treatment, often in hospitals, increases health-care costs and the 
achievements of modern medicine are put at risk by AMR. Without effective 
antimicrobials for care and prevention of infections, the success of treatments 
such as organ transplantation, cancer chemotherapy and major surgery would 
be compromised. The growth of global trade and travel allows resistant 
microorganisms to be spread rapidly to distant countries and continents 
through humans and food.  
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Background 
 After drug companies began producing penicillin in 1943, microbes 
began appearing that could resist it; Staphylococcus aureus was the first 
bacterium to have found a successful adaptation to resist this ground-
breaking antibiotic drug. This is caused by a combination of overuse, 
particularly to treat minor ornon-bacterial infections or to extend prophylaxis 
beyond 24 hours; misuse due to faulty diagnosis or lack of information about 
alternative appropriate treatments; and underuse. The use of antibiotics in 
animals sometimes exceeds their use in humans. The development of 
resistance not only in viruses to antiviral drugs such as those used in 
antiretroviral therapy of HIV/AIDS or against influenza, but also in parasites 
to anti parasitic drugs such as artemisin in against malaria and in fungi to 
antifungal agents. Through selective pressure, a new strain of any micro-
organism may emerge that resists antimicrobial drugs. 
 The problem of antimicrobial resistance was clearly identified in the 
early 1970s, and the first World Health Assembly resolution to call attention 
to the prudent use of drugs, including antibiotics, was adopted in 1984(1). 
Several other Health Assembly resolutions have drawn 
attention to antimicrobial resistance, and the WHO global strategy for 
containment of antimicrobial resistance, published in 2001(2), outlines the 
major directions for surveillance, prevention and control. It was followed in 
2005 by resolution (3)WHA 58.27 calling on countries to improve their 
response to the increasing problem of antimicrobial resistance. EU countries, 
in the WHO European Region have developed national action plans in 
response to the 2001 Council Recommendation (4) on the prudent use of 
antimicrobial agents in human medicine.  
 Health care systems in many countries in the European Region are 
still in different phases 
 of reform and transition where, with a few exceptions. Not enough 
has yet been done to regulate for the prudent use of antibiotics, or to propose 
overall guidance on the use of antibiotics in the community and hospital 
settings. A number of countries still do not have systems for surveillance of 
antibiotic resistance, antibiotic use and hospital-acquired infections, and 
there is still very little access to sensitivity testing to guide the use of 
antibiotics, even in life-threatening bloodstream or respiratory infections. 
Health care-associated infections are an additional driving force behind the 
emergence and spread of antibiotic resistance. There is little education 
about the prudent use of antibiotics in medical, veterinary and other health 
related professions, leading to overprescribing and misuse. The lack of new 
drugs against bacterial infections is further a challenge to combating and 
preventing bacterial infections. 
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 The antibiotic resistance is not properly documented through 
systematic surveillance systems.  
 
Literate review 
The situation in Europe. 
 Every year in the European Union alone, an estimated 25 000 patients 
die because of a serious resistant bacterial infection acquired in hospitals.  
 Antibiotic use in Europe, expressed in defined daily dose (DDD) per 
1000 inhabitants, ranges from 10.0 in the Russian Federation, 14.6 in 
Sweden to 45.2 in Greece, according to 2008 data from the European 
Surveillance of Antimicrobial Consumption (ESAC) project. The statistics 
depend on the strength of monitoring systems. In the European Union (EU), 
Norway and Iceland, 5–12% of hospital patients acquire an infection during 
their stay. Each year, an estimated 400 000 present with a resistant strain, of 
whom 25 000 die, on average. AMR has huge economic implications. 
Multidrug-resistant bacteria in the EU are estimated to cause an economic 
loss of more than €1.5 billion each year. 
 
New WHO report 
 The new report of WHO published in The Lancet Infectious Diseases 
(5) on 20 March 2014, is the first to release data on total antibiotic 
consumption for countries outside the European Union (EU). The data (from 
2011) indicate an almost fourfold difference between the lowest and the 
highest antibiotic users among 42 countries and regions in the WHO 
European Region (within and outside the EU). 
 
Table 1 (12) 
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 When compared to EU countries, some study participants ranked as 
top consumers (Montenegro, Tajikistan and Turkey) and others as low 
consumers (Armenia, Azerbaijan, Belarus and Bosnia and Herzegovina). 
Low antibiotic use may reflect underuse due to limited access to medicines 
for significant parts of the population. In Belarus, for example, this might be 
the consequence of a policy for universal access to health services. 
Penicillin’s were the most frequently used by all participants, with a 
generally high use of broad-spectrum penicillin (amoxicillin and ampicillin), 
especially in the newly independent states (NIS). Participants in south-
eastern Europe consumed high volumes of first-generation cephalosporins, 
comparable to use in northern EU countries. Montenegro and Serbia in 
particular used the long-acting macrolide azithromycin. Remarkably high use 
of parenteral antibiotic treatment was observed in all the NIS.  
 
Situation in Albania. 
Prescriptions and consumption (6) 
• Total antibiotic consumption is too high. This indicates that 
antibiotics are overprescribed and that the population has easy access 
to antibiotics in pharmacies through over-the-counter sales.  
• Wide-spectrum antibiotics are overused. This suggests that they are 
overprescribed, diagnostic tools are inappropriate and both 
prescribers and population have limited knowledge of antimicrobial 
resistance;  
• The seasonal fluctuations in consumption indicate that antibiotics are 
improperly used to treat seasonal viral infections.  
• Particular brands of antibiotics are overused and misused. This may 
result from marketing by the pharmaceutical industry, as well as 
insufficient knowledge in prescribers and the general public.  
 
Factors that accelerate the emergence and spread of AMR include: 
• lack of a comprehensive and coordinated response;  
• weak or absent antimicrobial resistance surveillance and monitoring 
systems;  
• inadequate systems to ensure quality and uninterrupted supply of 
medicines;  
• inappropriate use of antimicrobial medicines; 
• poor infection prevention and control practices; 
• insufficient diagnostic, prevention and therapeutic tools.  
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Good practice 
Georgia 8 
 Georgia is developing a cross-cutting strategy for antimicrobial 
resistance (AMR) that has the potential to not only alter the pattern of 
resistance in the country, but also to enhance the quality of health care 
overall. 
 A team of international experts visited Georgia on 10-14 February 
2014 to prepare recommendations for the Georgian Strategic Action plan 
Against AMR and to support establishment of the National Center for 
Disease Control (NCDC) Lugar Center as an AMR Public Health Reference 
Center for Georgia.  
 The mission ended with a debriefing at the Ministry of Labor, Health 
and Social Affairs, during which the following steps were proposed: 
• formation of a National Coordination Committee on AMR; 
• organization of a technical workshop to aid the formation of a 
network of  high-quality laboratories in Georgia;  
• planning of a high-level stakeholder meeting later in the year to 
present the Georgian AMR Strategic Action Plan. 
 
Turkey 9 
 On 4–5 December 2013, the first national antimicrobial resistance 
(AMR) laboratory surveillance network (NAMRS) meeting was organized in 
Ankara, Turkey by the WHO Country Office and the Ministry of Health 
within the scope of the European Union funded Surveillance and Control of 
Communicable Diseases project. Technical support was provided by 
WHO/Europe. Representatives from 77 participating laboratories, members 
of  the AMR scientific advisory board and WHO experts attended the 
meeting, which focused on 4 main themes:  
• the importance of  standardization, standard  operating  procedures  
and  quality assurance  to  improve  laboratory  practice  to support  
patient  treatment  and  antibiotic stewardship;  
• the  need  for  standardization  of  data collection, by  using  uniform  
laboratory codes;  
• how  to organize transition to the  European  Committee of  
Antimicrobial   Susceptibility Testing (EUCAST) guidelines and  the  
need  for EUCAST  laboratory training  in  this respect;  
• participation of Turkey in the Central Asian  and  Eastern  European  
Surveillance on Antimicrobial  Resistance (CAESAR)  network.  
 
Netherland 
 Resistance is a relatively small problem in the Netherlands thus far, 
but is regarded as a threat as it is a much greater problem in most other 
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countries. This is shown year after year by the surveillance data reported 
annually by EARS-NET (European Antimicrobial Resistance Surveillance 
System of ECDC) (10). This is because the only way to get antibiotics in the 
Netherlands is if a doctor prescribes them for you. Doctors only prescribe 
antibiotics  when  it  is  necessary, so  not  in case of  viral  infections  such  
as flu or a cold. Furthermore, healthcare institutions are aware of this 
problem. If someone in a hospital or nursing home is infected with resistant 
bacteria, this patient is cared for in isolation and the nursing staff involved 
take strict hygiene measures. The latest report on monitoring of antimicrobial 
resistance and antibiotic usage in animals in the Netherlands (11) shows that 
total sales of antibiotics for veterinary use have dropped by approximately 
50% between 2007 and 2012. Veterinarians also prescribe antibiotics, mainly 
for livestock farms, the use of antibiotics in animals has been greatly 
reduced. 
 
Italia 
 Resistance to antibiotics is higher in countries of southern and eastern 
Europe, including Italy. In Italy it is monitored by project AR - ISS, a 
sentinel surveillance coordinated by the "Instituto Superiore di Sanita”, 
which throws surveillance data to EARS - Net. 7 Italy is in the group of 
countries with the highest levels of resistance in pathogenic species most 
watched. Multi- sectorial interventions involving the use of antibiotics and 
infection control strategies in all areas of health care, are necessary to 
prevent a further increase in resistance to antibiotics and maintained at least 
in part, the effectiveness of these drugs. 
 
Recommandation  
• Policy-makers play a key role in tackling the emerging public health 
problem of antibiotic resistance. 
• The complexity of the problem and the large number of sectors 
involved require strong national coordination, surveillance systems, 
national guidelines and sector-wide action plans.  
• There are also good examples of national coordination: in some north 
European countries, all-inclusive national coordinating committees 
give advice on all matters regarding the prudent use of antibiotics and 
surveillance and prevention of antibiotic resistance. They provide 
guidelines on the use of antibiotics, steer awareness campaigns, 
advise on health professionals’ curriculum development and draw up 
national regulations. 
• As guidance for national policy-makers, the WHO Regional Office 
for Europe has developed a seven point strategic action plan that have 
to be launched in Albania also. 
European Scientific Journal December 2015 edition vol.11, No.36 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
110 
• The following seven strategic objectives are developed as guidance to 
national 
governments to address the complex factors that relate to bacterial 
resistance and its driver, 
antibiotic usage (especially overuse and misuse). They take into 
account the technical, financial, regulatory, educational and 
behavioral aspects that need to be addressed in comprehensive 
national plans of action. The regional strategic action plan should be 
used by policy-makers and other national stakeholders as an initial 
framework on which national action plans, guidance, regulations and 
organizational arrangements can based. 
I. Strengthen national multi sectorial coordination for the 
containment of antibiotic resistance 
II. Strengthen national surveillance of antibiotic resistance 
III.  Promote national strategies for the rational use of antibiotics and 
strengthen national surveillance of antibiotic consumption 
IV. Strengthen infection control and surveillance of antibiotic 
resistance in health care settings 
V. Prevent and control the development and spread of antibiotic 
resistance in the food chain 
VI. Promote innovation and research on new drugs and technology 
VII. Improve awareness, patient safety and partnership 
These objectives further emphasize the need to better understand the 
underlying causes of antibiotic resistance and to develop laboratory capacity 
in order to monitor national trends in antibiotic resistance, especially in life-
threatening infections but also with regard to emerging mechanisms of 
resistance that can further affect the treatment and prevention of bacterial 
infections in outpatient settings. These monitoring and surveillance systems 
should also be linked to mechanisms for international reporting of antibiotic 
resistance and consumption, since the globalization of travel and trade 
facilitates their international spread. 
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